


Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1. (Currently amended) A compound having the formula



~~the~~ a *N*-oxide form[[s]], ~~the~~ a pharmaceutically acceptable addition salt[[s]] ~~and or~~
~~the~~ a stereochemically isomeric form[[s]] thereof, wherein:

m represents an integer being 0 or 1;

n represents an integer being 0, 1 or 2;

R¹ represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl or C₁₋₄alkyl substituted with phenyl, pyridinyl or morpholinyl,
phenyl or phenyl substituted with one or where possible more substituents each independently being selected from C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, -NO₂ or cyano-C₁₋₄alkyl,
piperidinyl or piperidinyl substituted with one or where possible more substituents each independently being selected from C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl or phenyl-C₁₋₄alkyl,
phenyl-C₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;

R² represents hydrogen, phenyl, C₁₋₄alkyl or C₁₋₄alkyl substituted with phenyl or hydroxy;

R³ represents hydrogen, phenyl, C₁₋₄alkyl or C₁₋₄alkyl substituted with phenyl or hydroxy; or

R² and R³ taken together with the carbon atom to which they are attached form a C₃₋₈cycloalkyl or Het¹ wherein said C₃₋₈cycloalkyl or Het¹ each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C₁₋₄alkyloxycarbonyl, phenylcarbonyl

- C₁₋₄alkylsulfonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or -C(=NH)-NH₂;
- R⁴ represents halo, hydroxy, hydroxyC₁₋₄alkyl or C₁₋₄alkyloxy;
- R⁵ represents formyl, C₁₋₄alkyl, C₁₋₄alkyloxy, Het², -NO₂, -SO₂-Het⁶, aminosulfonyl, -SO₂-NR¹²R¹³,
- C₁₋₄alkyl substituted with one or where possible more substituent being selected from hydroxy, halo, Het³, NR⁶R⁷ or formyl,
- C₁₋₄alkyloxy substituted with one or where possible more substituents being selected from Het⁴, NR⁸R⁹ or -C(=O)-Het⁴;
- R⁶ and R⁷ are each independently selected from hydrogen, C₁₋₄alkyl, -Het⁵, aminosulphonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, C₁₋₄alkylsulfonyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkyloxyC₁₋₄alkyl, methoxyC₁₋₄alkyl or C₁₋₄alkyl substituted with one or where possible more substituents being selected from hydroxy, Het⁵, C₁₋₄alkyloxycarbonyl or C₁₋₄alkylsulfonyl;
- R⁸ and R⁹ are each independently selected from hydrogen, mono- or di(C₁₋₄alkyl)aminosulphonyl or aminosulphonyl;
- R¹² and R¹³ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl;
- Het¹ represents piperidinyll;
- Het² represents a heterocycle selected from piperidinyll or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C₁₋₄alkyloxycarbonyl;
- Het³ represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyll, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, hydroxyC₁₋₄alkyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, NR¹⁰R¹¹, imidazolyl, tetrahydropyrimidinyl, amino, NH₂-SO₂-O-, mono- or di(C₁₋₄alkyl)amino- SO₂-O-, NH₂-SO₂-NH-, mono- or di(C₁₋₄alkyl)amino- SO₂-NH-, hydroxyC₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl or C₁₋₄alkyloxy;
- R¹⁰ and R¹¹ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, or mono- or di(C₁₋₄alkyl)aminosulfonyl;
- Het⁴ represents a heterocycle selected from morpholinyl, piperidinyll or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each

independently selected from C₁₋₄alkyl, aminosulphonyl, mono- or di(C₁₋₄alkyl)aminosulphonyl or C₁₋₄alkyl substituted with one or more hydroxy;
Het⁵ represents a heterocycle selected from pyridinyl, pyrrolidinyl, or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C₁₋₄alkyl, aminosulphonyl, C₁₋₄alkyloxycarbonyl or mono- or di(C₁₋₄alkyl)aminosulphonyl;
Het⁶ represents morpholinyl.

2. (Currently amended) A compound according to claim 1 wherein;
m represents an integer being 0 or 1;
n represents an integer being 0, 1 or 2;
R¹ represents C₁₋₄alkyl ~~preferably methyl~~, C₁₋₄alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C₁₋₄alkyloxycarbonyl;
R² represents hydrogen or C₁₋₄alkyl ~~preferably methyl~~;
R³ represents hydrogen or C₁₋₄alkyl ~~preferably methyl~~; or
R² and R³ taken together with the carbon atom to which they are attached form cyclopentyl or piperidinyl wherein said cyclopentyl or piperidinyl each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C₁₋₄alkyloxycarbonyl, phenylcarbonyl or -C(=NH)-NH₂;
R⁴ represents halo or C₁₋₄alkyloxy;
R⁵ represents Het², C₁₋₄alkyl substituted with one or where possible more substituents being selected from hydroxy, halo, Het³ or NR⁶R⁷, or R⁵ represents C₁₋₄alkyloxy substituted with one or where possible more substituents being selected from Het⁴ or -C(=O)-Het⁴;
R⁶ and R⁷ are each independently selected from hydrogen, C₁₋₄alkyl, Het⁵ or C₁₋₄alkyl substituted with one or where possible more substituents being selected from hydroxy or Het⁵;
Het² represents piperazinyl;
Het³ represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C₁₋₄alkyl ~~preferably methyl~~, aminosulphonyl,

mono- or di(C₁₋₄alkyl)aminosulfonyl, hydroxyC₁₋₄alkyloxyC₁₋₄alkyl,
C₁₋₄alkyloxyC₁₋₄alkyl or C₁₋₄alkyloxy;

Het⁴ represents a heterocycle selected from morpholinyl or piperazinyl wherein
said monocyclic heterocycles each independently may optionally be
substituted with one, or where possible two or three C₁₋₄alkyl substituents,
~~preferably methyl~~;

Het⁵ represents a heterocycle selected from pyridinyl, pyrrolidinyl or piperidinyl
wherein said monocyclic heterocycles each independently may optionally be
substituted with one, or where possible two or three substituents each
independently selected from aminosulfonyl, C₁₋₄alkyloxycarbonyl or mono-
or di(C₁₋₄alkyl)aminosulfonyl.

3. (Currently amended) A compound according to claim 1 wherein;

m represents an integer being 0 or 1;

n represents an integer being 0, 1 or 2;

R¹ represents C₁₋₄alkyl ~~preferably methyl~~, C₁₋₄alkyl substituted with phenyl, or R¹
represents piperidinyl or piperidinyl substituted with C₁₋₄alkyloxycarbonyl;

R² represents hydrogen, phenyl, C₁₋₄alkyl or C₁₋₄alkyl substituted with phenyl;

R² R³ represents hydrogen, phenyl, C₁₋₄alkyl or C₁₋₄alkyl substituted with phenyl;
or

R² and R³ taken together with the carbon atom to which they are attached form
cyclopentyl or piperidinyl wherein said cyclopentyl or piperidinyl each
independently may optionally be substituted with one, or where possible, two
or three substituents each independently selected from C₁₋₄alkyloxycarbonyl,
C₁₋₄alkylsulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or phenylcarbonyl;
R⁴ represents halo, ~~preferably Cl~~ or R⁴ represents C₁₋₄alkyloxy ~~preferably~~
~~methoxy~~;

R⁵ represents formyl, C₁₋₄alkyl substituted with one or where possible more
substituent being selected from hydroxy, Het³ or NR⁶R⁷, or R⁵ represents
C₁₋₄alkyloxy substituted with one or where possible more substituents being
selected from Het⁴ or -C(=O)-Het⁴;

R⁶ and R⁷ are each independently selected from hydrogen, C₁₋₄alkyl, -Het⁵,
C₁₋₄alkylsulfonyl, methoxyC₁₋₄alkyl, or C₁₋₄alkyl substituted with one or
where possible more substituents being selected from hydroxy or Het⁵;

Het² represents piperidinyl optionally substituted with C₁₋₄alkyloxycarbonyl;

Het³ represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl,
or piperazinyl wherein said monocyclic heterocycles each independently may

optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, hydroxyC₁₋₄alkyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, NR¹⁰R¹¹, imidazolyl, tetrahydropyrimidinyl, amino, hydroxyC₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl or C₁₋₄alkyloxy; R¹⁰ and R¹¹ are each independently selected from hydrogen or C₁₋₄alkyl; Het⁴ represents a heterocycle selected from morpholinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three C₁₋₄alkyl substituents, ~~preferably methyl~~;

Het⁵ represents a heterocycle selected from pyridinyl, pyrrolidinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C₁₋₄alkyl, aminosulfonyl, C₁₋₄alkyloxycarbonyl or mono- or di(C₁₋₄alkyl)aminosulfonyl.

4. (Currently Amended) A compound as claimed in claim 1, wherein R² and R³ taken together with the carbon atom to which they are attached form a C₃₋₈cycloalkyl, ~~preferably cyclopentyl~~.
5. (Currently Amended) A compound as claimed in claim 1, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with Het⁴, said Het⁴ is being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C₁₋₄alkyl, ~~preferably methyl~~.
6. (Currently Amended) A compound as claimed in claim 1, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with -C(=O)-Het⁴, said Het⁴ consists of piperazinyl ~~preferably substituted with C₁₋₄alkyl~~.
7. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective kinase inhibitory amount of a compound as described in claim 1.
8. (Previously presented) A process of preparing a pharmaceutical composition as defined in claim 7, comprising a pharmaceutically acceptable carrier is intimately mixed with an effective kinase inhibitory amount of a compound as described in claim 1.


9. (Cancelled)

10. (Cancelled)


11. (Currently Amended) A process of preparing a compound as described in claim 1, comprising

i) reacting a primary amine of formula (V) with an aldehyde of formula (VI);

wherein Q is defined as




in a condensation reaction using ethanol as a suitable solvent;



e) EtOH

ii) followed by a nitrosative cyclisation of the thus obtained Schiff's bases of formula (II) with NaNO_2 in acetic acid, and refluxing the nitroso intermediates of formula (III) in a suitable solvent such as acetic anhydride or ethanol further comprising dithiothreitol (DTT);



a) NaNO_2 , AcOH, H_2O b) DTT, EtOH

12. (Currently amended) A compound as claimed in claim 2, wherein R² and R³ taken together with the carbon atom to which they are attached form a C₃₋₈cycloalkyl, ~~preferably cyclopentyl~~.
13. (Currently amended) A compound as claimed in claim 3, wherein R² and R³ taken together with the carbon atom to which they are attached form a C₃₋₈cycloalkyl, ~~preferably cyclopentyl~~.
14. (Currently amended) A compound as claimed in claim 2, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with Het⁴, said Het⁴ is ~~being~~ selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C₁₋₄alkyl, ~~preferably methyl~~.
15. (Currently amended) A compound as claimed in claim 3, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with Het⁴, said Het⁴ is ~~being~~ selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C₁₋₄alkyl, ~~preferably methyl~~.
16. (Currently amended) A compound as claimed in claim 4, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with Het⁴, said Het⁴ is ~~being~~ selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C₁₋₄alkyl, ~~preferably methyl~~.
17. (Currently amended) A compound as claimed in claim 2, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with -C(=O)-Het⁴, said Het⁴ consists of piperazinyl ~~preferably substituted with C₁₋₄alkyl~~.
18. (Currently amended) A compound as claimed in claim 3, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with -C(=O)-Het⁴, said Het⁴ consists of piperazinyl ~~preferably substituted with C₁₋₄alkyl~~.
19. (Currently amended) A compound as claimed in claim 4, provided that when R⁵ represents a C₁₋₄alkyloxy substituted with -C(=O)-Het⁴, said Het⁴ consists of piperazinyl ~~preferably substituted with C₁₋₄alkyl~~.